BTIG raised the firm’s price target on Viking Therapeutics (VKTX) to $31 from $20 and keeps a Buy rating on the shares. The firm is impressed by the attractive early clinical profile of VK2735 with significant weight loss after just 28-days of treatment with good tolerability, and views the positive data release as a de-risking event for the asset, with an initial clinical profile that is strongly competitive to Eli Lilly’s (LLY) Mounjaro and appears more efficacious than Novo’s (NVO) semaglutide, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics price target raised to $30 from $20 at Oppenheimer
- Stifel reiterates Buy on Viking Therapeutics, raises price target to $25
- Viking’s VK2735 looks like ‘heavyweight contender,’ says H.C. Wainwright
- VKTX Soars on Promising VK2735 Data
- Viking Therapeutics initiates Phase 1 study of novel formulation of VK2735
